Michael Powell, Director at Orexigen Therapeutics, Inc. (OREX), sold 825,000 shares at $8.09 ($6.8M) on 2010-12-23, disclosed to the SEC on 2010-12-23.
Open-market sale of $6.8M OREX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.38 | 4,204 | $35K | 0.5% |
| 2 | $8.38 | 61,405 | $515K | 7.5% |
| 3 | $8.38 | 309,730 | $2.6M | 38.0% |
| 4 | $8.30 | 2,808 | $23K | 0.3% |
| 5 | $8.30 | 41,018 | $340K | 5.0% |
| 6 | $8.30 | 206,895 |
| $1.7M |
| 25.1% |
| 7 | $8.09 | 2,293 | $19K | 0.3% |
| 8 | $8.09 | 32,358 | $262K | 3.8% |
| 9 | $8.09 | 164,289 | $1.3M | 19.4% |
| Total | $8.29 avg | 825,000 | $6.8M | 100% |
| Filing → |
| OCRX | SELL | 2016-12-30 | $15K | — | Filing → |
| MIRN | BUY | 2015-10-06 | $6.0M | — | Filing → |
| AERI | SELL | 2014-07-11 | $24.2M | — | Filing → |